
DBTX
Healthcare · Biotechnology · $123.4M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2023
EPS trend, 90 days to now · -30.5% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 11, 2023 | Before the open | -0.55 | -0.73 | -32.7% |
| May 15, 2023 | Before the open | -0.60 | -0.53 | +11.7% |
| Mar 14, 2023 | After the close | -0.40 | -0.63 | -57.5% |
| Nov 9, 2022 | After the close | -0.69 | -0.64 | +7.2% |
| Aug 10, 2022 | After the close | -0.57 | -0.68 | -19.3% |
| May 12, 2022 | Before the open | -0.56 | -0.56 | 0.0% |
| Mar 18, 2022 | Before the open | -0.47 | -0.49 | -4.3% |
| Nov 10, 2021 | Before the open | -0.43 | -0.59 | -37.2% |
| Aug 10, 2021 | Before the open | -0.37 | -0.47 | -27.0% |
| May 13, 2021 | After the close | -0.54 | -1.09 | -101.9% |
| Feb 11, 2021 | After the close | -10.35 | -0.46 | +95.6% |
| Dec 31, 2019 | Time not confirmed | 0.00 | -4.02 | — |
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations;…